Takeda Pharmaceutical Co Ltd (NYSE:TAK) stock is trading higher on Wednesday. Earlier today, the European Commission approved Takeda’s Adzynma (recombinant ADAMTS13) for treating ADAMTS13 deficiency in children and adult patients with congenital thrombotic thrombocytopenic purpura (cTTP). Congenital thrombotic thrombocytopenic purpura, also known as Upshaw-Schulman syndrome, is a rare inherited disorder that affects the blood’s ability to clot properly. This condition leads to the excessive form
Investors bought the beaten-down infrastructure stock ahead of earnings.
Axon Enterprise's second-quarter sales jumped and the TASER maker raised its full-year guidance on demand for its services.
Shares are still tanking after the global system outage in July. But can this embattled company recover?
